Orphazyme has asked for more time to address late-stage issues that the European Medicines Agency has about its EU marketing authorization application (MAA) for arimoclomol, an investigational treatment for the rare, genetic, progressively debilitating and often fatal Niemann-Pick disease type C.
The Danish company’s request to the EMA’s human medicines evaluation committee (the CHMP) for additional time comes months after arimoclomol...








